title: Emerging paradigms in targeted treatments for Asian patients with NSCLC.
abstract: BACKGROUND
  EGFR-targeted drugs have been successfully approved in many countries and have demonstrated higher efficacy and lower toxicity than chemotherapy in molecularly defined subgroups of patients. Significant advances in clinical trials and studies focusing on targeted therapies have rapidly developed in Asia.
  
  
  METHODS
  In the present review article, all of the published data or meeting abstracts on completed or ongoing trials of targeted treatment for Asian patients with NSCLC were collected and analyzed.
  
  
  CONCLUSIONS
  Routine molecular testing has been used clinically to identify mutations/fusions and guide patient selection for targeted therapies. Based on the evidence presented, we provided up-to-date treatment recommendations for Asian patients with advanced NSCLC. Future directions, including dividing Del19 and L858R patients into two distinct populations, will optimize therapeutic strategies for L858R patients and may inform rational trial design by considering the proportion of type of sensitive EGFR mutation as a stratification factor. Another important aspect to consider involves how to monitor resistance to TKIs, which will improve the outcome for lung cancer patients with driver gene mutations.
authors.affiliation: Southern Medical University , Guangzhou, Guangdong 510515 , PR China.
authors.forename: E-E
authors.initials: EE
authors.lastname: Ke
authors.forename: Qing
authors.initials: Q
authors.lastname: Zhou
authors.forename: Yi-Long
authors.initials: YL
authors.lastname: Wu
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D044466:Asian People; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics; D017024:Chemotherapy, Adjuvant; D017326:Clinical Trials, Phase III as Topic; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000235:genetics; D050939:Gene Fusion; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D058990:Molecular Targeted Therapy; D009154:Mutation; D020360:Neoadjuvant Therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors
keywords: Asian population; NSCLC; clinical trials; targeted therapy